Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 451

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 451
---
    Money market fund 
    $35,162  
    $35,162  
    $       -  
    $      - 
  
    Total cash equivalents 
    $35,162  
    $35,162  
    $-  
    $- 

F-13

NOTE 6 – LEASE

In September 2021, the Company signed a lease with a third party for
office space in Boca Raton, Florida. The lease agreement has a 64-month term and commenced during the fourth quarter of 2021.

Below is a summary of the Company’s right-of-use
assets and liabilities:

  (in thousands, except years and rate)  December 31, 2024   December 31, 2023   Right-of-use asset  $307   $414                Operating lease, current liability   140    119                Long-term operating lease liability   244    397   Total lease liability  $384   $516                Weighted-average remaining lease term   2.3 years    3.3 years                Weighted-average discount rate   12.0%   12.0% 

NOTE 7 – RELATED PARTY TRANSACTIONS

UCL

At December 31, 2024 and 2023,
the Company recorded $0 and $112,000, respectively, of prepaid expenses – related party for payments made to UCL in advance
of medical research to be provided. During the years ended December 31, 2024 and 2023, the Company paid UCL $321,000 and $573,000,
respectively. UCL is a wholly owned subsidiary of the University of London. The Company’s Chief Scientific and Manufacturing Officer
is a professor at the University of London.

AmplifyBio

During the
years ended December 31, 2024 and 2023, the Company paid AmplifyBio $384,000 and $77,000, respectively, to perform certain research and
development on behalf of the Company. The CEO of AmplifyBio is on the Board of Directors of the Company. 

NOTE
8 – DEBT

During 2021, the Company entered
into a Loan and Security Agreement (the “Term